Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Intrapatient Dose Titration Study of KER-047 in Participants With Functional Iron Deficiency Anemia Associated With Myelodysplastic Syndromes, Myelofibrosis, and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Next Previous
Trial Profile

A Phase 2, Intrapatient Dose Titration Study of KER-047 in Participants With Functional Iron Deficiency Anemia Associated With Myelodysplastic Syndromes, Myelofibrosis, and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KER 047 (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions
  • Sponsors Kereos

Most Recent Events

  • 21 Nov 2023 Status changed from recruiting to withdrawn prior to enrolment.
  • 18 Oct 2023 Planned initiation date (estimated date of first participant enrollment) changed from 31 Oct 2023 to 30 Nov 2023.
  • 17 Oct 2023 Planned initiation date (estimated date of first participant enrollment) changed from 30 Sep 2023 to 31 Oct 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top